First Time Loading...

Jasper Therapeutics Inc
NASDAQ:JSPR

Watchlist Manager
Jasper Therapeutics Inc Logo
Jasper Therapeutics Inc
NASDAQ:JSPR
Watchlist
Price: 23.98 USD 0.25% Market Closed
Updated: May 29, 2024

Jasper Therapeutics Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jasper Therapeutics Inc
Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Jasper Therapeutics Inc
NASDAQ:JSPR
Cash Equivalents
$86.9m
CAGR 3-Years
64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Equivalents
$18.1B
CAGR 3-Years
23%
CAGR 5-Years
30%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
Cash Equivalents
$4.7B
CAGR 3-Years
5%
CAGR 5-Years
-23%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash Equivalents
$9.7B
CAGR 3-Years
17%
CAGR 5-Years
6%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Equivalents
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
26%
CAGR 10-Years
36%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Equivalents
$2.6B
CAGR 3-Years
22%
CAGR 5-Years
9%
CAGR 10-Years
19%

See Also

What is Jasper Therapeutics Inc's Cash Equivalents?
Cash Equivalents
86.9m USD

Based on the financial report for Dec 31, 2023, Jasper Therapeutics Inc's Cash Equivalents amounts to 86.9m USD.

What is Jasper Therapeutics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
64%

Over the last year, the Cash Equivalents growth was 127%. The average annual Cash Equivalents growth rates for Jasper Therapeutics Inc have been 64% over the past three years .